CN114539092A - Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of itching-relieving products - Google Patents
Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of itching-relieving products Download PDFInfo
- Publication number
- CN114539092A CN114539092A CN202210248498.8A CN202210248498A CN114539092A CN 114539092 A CN114539092 A CN 114539092A CN 202210248498 A CN202210248498 A CN 202210248498A CN 114539092 A CN114539092 A CN 114539092A
- Authority
- CN
- China
- Prior art keywords
- alkaloid
- oat
- oat bran
- preparation
- phenolic amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 63
- -1 phenolic amide alkaloid Chemical class 0.000 title claims abstract description 48
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 47
- 229940038580 oat bran Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000003756 stirring Methods 0.000 claims abstract description 18
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 15
- 239000007821 HATU Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000001704 evaporation Methods 0.000 claims abstract description 9
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 230000008034 disappearance Effects 0.000 claims abstract description 8
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000012544 monitoring process Methods 0.000 claims abstract description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010048218 Xeroderma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 230000007870 cholestasis Effects 0.000 claims description 2
- 231100000359 cholestasis Toxicity 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010021198 ichthyosis Diseases 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 230000001139 anti-pruritic effect Effects 0.000 abstract description 13
- 230000007803 itching Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 4
- 235000007319 Avena orientalis Nutrition 0.000 description 61
- 244000075850 Avena orientalis Species 0.000 description 60
- 210000003491 skin Anatomy 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 229940126214 compound 3 Drugs 0.000 description 14
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 9
- 229930190481 Avenanthramide Natural products 0.000 description 9
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 9
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 description 7
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 7
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical class NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 6
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 6
- 229960000520 diphenhydramine Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940125898 compound 5 Drugs 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- 102100024304 Protachykinin-1 Human genes 0.000 description 3
- 101800003906 Substance P Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002308 glutamine derivatives Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 101100233695 Mus musculus Itch gene Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000209761 Avena Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101150033824 PAA1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of medicinal chemistry, and particularly discloses oat bran phenolic amide alkaloid, a preparation method thereof and application thereof in preparation of an itching relieving product. The oat bran phenolic amide alkaloid has a structure shown in a formula I or a formula II. The preparation method of the oat bran phenolic amide alkaloid specifically comprises the following steps: taking a reaction substrate caffeic acid analogue, adding an organic solvent, adding 4- (2-aminoethyl) phenol and triethylamine under stirring, and adding HATU after 3-6 minutes; after the feeding is finished, continuously reacting for 3-6 hours at room temperature, and monitoring the disappearance of reaction raw materials by TLC; stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography to obtain the oat bran phenolic amide alkaloid. Research shows that the oat bran phenolic amide alkaloid or the composition thereof has excellent antipruritic effect; therefore, the oat bran phenolic amide alkaloid or the composition thereof can be used for developing an anti-itching product.
Description
Technical Field
The invention relates to the technical field of medicinal chemistry, in particular to oat bran phenolic amide alkaloid, a preparation method thereof and application thereof in preparing an itching relieving product.
Background
Skin pruritus is the most common skin disease of the elderly, and antihistamines are common medicines for clinically treating skin pruritus. The balance of Th1/Th2 cells is closely related to the abnormal expression of inflammatory factors of patients with skin pruritus, and the fact that the abnormal expression of the inflammatory factors is remarkably increased by the Th1 cytokines in an atopic dermatitis rat model plays an important role in the pathogenesis of the skin pruritus, so that the anti-inflammatory treatment has a good effect on the clinical curative effect of the skin pruritus.
The traditional Chinese medicine has long history and rich experience in treating skin diseases, can control repeated skin diseases or prolong the recurrence time of the skin diseases, reduces or avoids the side effect of chemical drugs, delays the pathological change process and prolongs the survival time, so the trend of pursuing the traditional Chinese medicine with stable curative effect, safety and reliability is more and more obvious.
Oats are one of the major cereals worldwide and are recognized by the U.S. FDA as functional foods, an important source of protein, vitamins and various mineral elements. Research shows that the oat is rich in various active ingredients, wherein the avenanthramide is the main functional ingredient in the oat, has the functions of reducing blood fat, blood sugar and blood pressure and the like, and is related to the antioxidation of the oat. In addition, avenanthramides may mediate inflammatory cell responses through interactions with cytokines and signaling pathways, have anti-inflammatory and bacteriostatic effects, and colloidal extracts containing avenanthramides have been shown to have anti-histamine and anti-inflammatory activities. Avenanthramides have a variety of biological activities and are very beneficial to human and animal health. The application of the oat alkaloid is greatly limited by factors such as single structure of oat alkaloid, low content of oat and the like. Therefore, the method has important application value in improving and optimizing the structure based on the avenanthramide, synthesizing the analogue with the avenanthramide structure or the avenanthramide compound with better activity and developing the avenanthramide analogue with the function of resisting skin itch.
Disclosure of Invention
In view of the above, the invention firstly provides oat bracteoamide alkaloid with a brand-new structure, and researches show that the oat bracteoamide alkaloid has an antipruritic effect.
The detailed technical scheme of the invention is as follows:
an oat bran phenolic amide alkaloid having a structure represented by formula I or formula II:
wherein, formula I or R in formula II1、R2And R3Each independently selected from H, OH or OCH3。
Preferably, the oat bracteoamide alkaloid is any one of oat bracteoamide alkaloid-1-6; the structural formula of the oat bran phenolic amide alkaloid-1-6 is as follows:
the inventor finds that R in the compound shown in formula I or formula II1、R2And R3The oat bran phenolic amide alkaloid obtained after being substituted by different groups has great difference in itching relieving effect; the inventors are studyingSurprisingly, the oat bran phenolic amide alkaloid-3 has a far greater itching relieving effect than other compounds, and has a very remarkable itching relieving effect; the antipruritic effect of the compound is also obviously higher than that of the known avenanthramide and the positive control medicament diphenhydramine; significant technological advances have been made.
The present invention also provides a composition comprising oat spartinamide alkaloid-3 and oat spartinamide alkaloid-4; wherein the weight ratio of oat bracteoamide alkaloid-3 to oat bracteoamide alkaloid-4 is 1-5: 1;
further preferably, the weight ratio of the oat bracteoamide alkaloid-3 to the oat bracteoamide alkaloid-4 is 2-4: 1;
most preferably, the oat brazzolamide alkaloid-3 and oat brazzolamide alkaloid-4 are present in a weight ratio of 3: 1.
The inventors have surprisingly found in further studies that: synergistic antipruritic effects are not achieved by any combination of compounds; however, after the oat bracteoamide alkaloid-3 and the oat bracteoamide alkaloid-4 are combined, the two can generate a synergistic itching relieving effect, and the itching relieving effect is obviously higher than that of the oat bracteoamide alkaloid-3 or the oat bracteoamide alkaloid-4 alone.
The invention also provides a preparation method of the oat bran phenolic amide alkaloid, which is prepared by taking caffeic acid analogues and 4- (2-aminoethyl) phenol as raw materials;
the structure of the caffeic acid analog is as follows:
wherein R is1、R2、R3Independently selected from H, OH or OCH3。
Preferably, the molar ratio of the caffeic acid analog to 4- (2-aminoethyl) phenol is 1: 1-3.
Preferably, taking a reaction substrate caffeic acid analogue, adding an organic solvent, adding 4- (2-aminoethyl) phenol and triethylamine under stirring, and adding HATU after 3-6 minutes; after the feeding is finished, continuously reacting for 3-6 hours at room temperature, and monitoring by TLC that reaction raw materials disappear; stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography to obtain the oat bran phenolic amide alkaloid.
Preferably, the dosage ratio of the organic solvent, the triethylamine and the HATU to the reaction substrate caffeic acid analogues is 30-60 mL: 5-6 mL: 4.5-5.0 g:1 g.
Most preferably, the ratio of the organic solvent, triethylamine and HATU to the reaction substrate caffeic acid analog is 40mL:5.5mL:4.85g:1 g.
The invention also provides the application of the compound or the composition in preparing an antipruritic product; the product comprises medicine, skin care product or cosmetic.
Preferably, the itch is itch caused by dermatitis, burns, eczema, urticaria, xeroderma, superficial fungal infection, or psoriasis.
Preferably, the itch is itch caused by diabetes, cholestasis, chronic kidney disease, tumors, or aids.
Has the advantages that: (1) the oat bran phenolic amide alkaloid compound can obviously inhibit the excessive secretion of inflammatory cytokines of mice with skin pruritus; (2) the oat bran phenolic amide alkaloid compound can obviously reduce scratching times of mice with skin itch; (3) in particular to the composition formed by combining oat bracteoamide alkaloid-3, oat bracteoamide alkaloid-3 and oat bracteoamide alkaloid-4, which has stronger anti-inflammatory and antipruritic activities than diphenhydramine and the known compound oat alkaloid; the oat bran phenolic amide alkaloid or the composition thereof can be used for developing an anti-itching product; (4) the method has the characteristics of rapid reaction, simple steps, high yield, high product purity, economy and applicability.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only drawings of some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
FIG. 1 is a schematic representation of oat bran phenolic amide alkaloid compound-11H-NMR spectrum.
FIG. 2 is a schematic representation of oat bran phenolic amide alkaloid compound-113C-NMR spectrum.
FIG. 3 is a preparation of oat bran phenolic amide alkaloid compound-21H-NMR spectrum.
FIG. 4 shows the preparation of oat bran phenolic amide alkaloid compound-213C-NMR spectrum.
FIG. 5 is a preparation of oat bran phenolic amide alkaloid compound-31H-NMR spectrum.
FIG. 6 shows the preparation of oat bran phenolic amide alkaloid compound-313C-NMR spectrum.
FIG. 7 shows the preparation of oat bran phenolic amide alkaloid compound-41H-NMR spectrum.
FIG. 8 shows the preparation of oat bran phenolic amide alkaloid compound-513C-NMR spectrum.
FIG. 9 shows the preparation of oat bran phenolic amide alkaloid compound-51H-NMR spectrum.
FIG. 10 shows the preparation of oat bran phenolic amide alkaloid compound-513C-NMR spectrum.
FIG. 11 shows the preparation of oat bran phenolic amide alkaloid compound-61H-NMR spectrum.
FIG. 12 is a preparation of oat bran phenolic amide alkaloid compound-613C-NMR spectrum.
Detailed Description
The technical solution of the present invention will be clearly and completely described with reference to the following examples. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
preparation of oat Glutamine amide alkaloid compound-1 (abbreviated as PAA-1) compound
(E) -3- (4-hydroxy-3-methoxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-1. The structure is as follows:
example 2:
preparation of oat Glutamine amide alkaloid compound-2 (abbreviated as PAA-2) compound
(E) -3- (4-hydroxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-2. The structure is as follows:
example 3:
preparation of oat Glutamine amide alkaloid compound-3 (abbreviated as PAA-3) compound
(E) -3- (3,4-dihydroxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-3. The structure is as follows:
example 4:
preparation of oat Glutamine amide alkaloid compound-4 (abbreviated as PAA-4) compound
(E) -3- (3,4-dihydroxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-4. The structure is as follows:
example 5:
preparation of oat Glutamine amide alkaloid Compound-5 (abbreviated as PAA-5)
(E) -3- (4-hydroxy-3-methoxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethylnol) -2-methoxyphenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-5. The structure is as follows:
example 6:
preparation of oat Glutamine amide alkaloid Compound-6 (abbreviated as PAA-6)
(E) -3- (4-hydroxy-3,5-dimethoxyphenyl) acrylic acid (1.0g) was weighed into a 100mL clean round bottom flask, magneton was placed, 40mL of anhydrous dichloromethane was added, 4- (2-aminoethyl) phenol (1.84g), triethylamine (5.5mL) was added with stirring, and HATU (4.85g) was added after 5 minutes. After the end of the addition, the reaction was continued at room temperature for 5 hours and the disappearance of the reaction material was monitored by TLC. Stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography (200-300 mesh) to obtain oat bracteoamide alkaloid compound-6. The structure is as follows:
experimental example:
the invention utilizes a mouse skin itch model inhibition experiment to confirm the itch relieving activity of the oat bran phenolic amide alkaloid compound and the composition. The enzyme-linked immunosorbent assay is used for detecting the content of IL-1 beta, IL-4, PAR-2 and P substances in serum.
Antipruritic activity of the oat bran phenolic amide alkaloid compounds and compositions of the present invention
Kunming mice, SPF level, male, weight (35 +/-2) g, feeding in a constant temperature environment at 20 +/-2 ℃ and humidity of 40% -70%, wherein the feeding environment is a light rhythm of 12h:12h (7:00-19:00), feeding freely with water, and feeding adaptively for 1 week. Randomly dividing mice into a normal group, a skin itch model group, a diphenhydramine group, an oat alkaloid group, oat branoxamine alkaloid compounds-1-6 groups and an oat branoxamine alkaloid compound composition group (the mass ratio of oat branoxamine alkaloid compound-3 to oat branoxamine alkaloid compound-4 is 1:1), and 10 mice in each group. After the start of the experiment, the neck and back of each group of mice were injected with 125 mg/kg of D-galactose injection subcutaneously for 6 weeks (the normal group was given the same amount)Dose saline). Starting at week 7, mice in each group were dosed at 0.5mg/cm2The application is carried out 1 time in the evening for 7 days (the normal group and the skin aging and pruritus model group are respectively provided with distilled water with the same dose every day). In the experiment process, the hair of the neck and the back of the mouse is shaved by scissors, so that no hair exists on the neck and the back of the mouse.
TABLE 1 Effect of oat Glutamine alkaloid Compounds on mouse itch latency and itch frequency
Note comparison with skin itch model group*p＜0.05,**p＜0.01.
As can be seen from the experimental data in Table 1, the incubation time of oat branoxamide alkaloid compound-3 (PAA-3) to mouse itch is significantly longer than that of other oat branoxamide alkaloid compounds and the known oat alkaloids and the positive control drug diphenhydramine; it has significantly less itch times in mice than other oat bracteamide alkaloid compounds and known oat alkaloids and the positive control diphenhydramine. This indicates that: in the compounds of formula I or formula II1、R2And R3The oat bran phenolic amide alkaloid obtained after being substituted by different groups has great difference in itching relieving effect; the oat bran phenolic amide alkaloid-3 has a far greater antipruritic effect than other compounds, and has a very obvious antipruritic effect; the antipruritic effect of the compound is also obviously higher than that of the known avenanthramide and the positive control medicament diphenhydramine; significant technological advances have been made.
It can also be seen from the experimental data in table 1 that the antipruritic effect of oat brazzolamide alkaloid-3 and oat brazzolamide alkaloid-4 in combination is significantly higher than that of either oat brazzolamide alkaloid-3 or oat brazzolamide alkaloid-4 alone; the content of the compound is also obviously higher than that of the known avenanthramide and the positive control drug diphenhydramine; this shows that when oat bracteoamide alkaloid-3 and oat bracteoamide alkaloid-4 are combined, they can produce synergistic antipruritic effect.
In addition, we tested the effect of oat bran phenolic amide alkaloid compound-3 (PAA-3) of the present invention on IL-1 β, IL-4, PAR-2, substance P: the occurrence of cutaneous pruritus is important in relation to immune cells (eosinophils, mast cells, etc.) and inflammatory factors (interleukins, histamine, etc.). Mast cells are widely present around blood vessels of skin and tissues, and contain inflammatory factors such as histamine, heparin, 5-hydroxytryptamine, etc., and the mast cells and the inflammatory factors play important roles in the induction of allergic reactions. In addition, IL-1 β and IL-4 are common inflammatory factors in disease, and PAR is a member of the G-protein coupled receptor family. PAR-2 can promote the adhesion and migration of vascular endothelial leukocytes, promote the expression and release of IL-1 and the like, and has important proinflammatory effects and the effect of mediating tissue injury. At the same time, PAR-2 stimulates IL-4 secretion from mast cells. Therefore, after 1h of application on day 7, 0.025% low molecular dextran-40 injection was injected intravenously, and 30min later, the video camera recorded the scratching performance of the mice. The method comprises the steps of taking blood from eyeballs, centrifuging at 3000r/min for 10min, taking serum, and detecting the contents of IL-1 beta, IL-4, PAR-2 and P substances in the serum by an enzyme-linked immunosorbent assay.
TABLE 2 Effect of oat Glutamine alkaloid Compound-3 on mouse IL-1 β, IL-4
Note: comparison with Normal group#p＜0.05,##p is less than 0.01; comparison with skin itch model group*p＜0.05,**p＜0.01.
TABLE 3 Effect of oat Glutamine alkaloid Compound-3 on mouse serum PAR-2
Note: comparison with Normal group#p＜0.05,##p is less than 0.01; comparison with skin itch model group*p＜0.05,**p＜0.01.
TABLE 4 Effect of oat Glutamine alkaloid Compound-3 on mouse serum substance P
Note: comparison with Normal group#p＜0.05,##p is less than 0.01; comparison with skin itch model group*p＜0.05,**p＜0.01.
As can be seen from the data in Table 2, IL-1. beta. was significantly increased and IL-4 was significantly decreased in the skin pruritus model group, as compared with the normal group. Compared with the skin itch model group, the IL-1 beta of the oat bracteamide alkaloid compound-3 group is remarkably reduced and the IL-4 is remarkably increased after the medicine is taken, which shows that the oat bracteamide alkaloid compound-3 has the function of relieving the skin itch. As can be seen from the data in Table 3, the skin itch model group had significantly increased PAR-2 content compared to the normal group. After administration, the PAR-2 content of oat bran phenolic amide alkaloid compound-3 group was significantly reduced compared to the skin itch model group. As can be seen from the data of table 4, substance P was significantly increased in the skin itch model group compared with the normal group. After administration, oat bran phenolic amide alkaloid compound-3 group P substance was significantly reduced compared to the skin itch model group.
The above deep level of mechanism research description; oat bran phenolic amide alkaloid compounds or compositions may be used to achieve antipruritic effects by modulating reduced expression of PAR-2 and substance P, and reduced secretion of inflammatory cytokines.
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (10)
1. An oat bran phenolic amide alkaloid having a structure represented by formula I or formula II:
wherein, formula I or R in formula II1、R2And R3Each independently selected from H, OH or OCH3。
2. The oat bracteoamide alkaloid of claim 1, which is selected from any one of oat bracteoamide alkaloid-1-6; the structural formula of the oat bran phenolic amide alkaloid-1-6 is as follows:
3. a composition comprising phenamide alkaloid-3 and phenamide alkaloid-4; wherein the weight ratio of oat bracteoamide alkaloid-3 to oat bracteoamide alkaloid-4 is 1-5: 1;
further preferably, the weight ratio of the oat bracteoamide alkaloid-3 to the oat bracteoamide alkaloid-4 is 2-4: 1;
most preferably, the oat brazzolamide alkaloid-3 and oat brazzolamide alkaloid-4 are present in a weight ratio of 3: 1.
4. A method for preparing oat bran phenolic amide alkaloid having a structure as shown in claim 1 or 2, characterized in that the oat bran phenolic amide alkaloid is prepared by using caffeic acid analogues and 4- (2-aminoethyl) phenol as raw materials;
the structure of the caffeic acid analog is as follows:
wherein R is1、R2、R3Independently selected from H, OH or OCH3。
5. The method according to claim 4, wherein the molar ratio of the caffeic acid analog to 4- (2-aminoethyl) phenol is 1:1 to 3.
6. The method according to claim 4, comprising the steps of: taking a reaction substrate caffeic acid analogue, adding an organic solvent, adding 4- (2-aminoethyl) phenol and triethylamine under stirring, and adding HATU after 3-6 minutes; after the feeding is finished, continuously reacting for 3-6 hours at room temperature, and monitoring the disappearance of reaction raw materials by TLC; stopping stirring, evaporating the reaction system under reduced pressure to remove the solvent, and purifying the residue by silica gel column chromatography to obtain the oat bran phenolic amide alkaloid.
7. The preparation method according to claim 4, wherein the amount ratio of the organic solvent, triethylamine and HATU to the reaction substrate caffeic acid analog is 30-60 mL: 5-6 mL: 4.5-5.0 g:1 g;
most preferably, the ratio of the organic solvent, triethylamine and HATU to the caffeic acid analog of the reaction substrate is 40mL:5.5mL:4.85g:1 g.
8. Use of a compound or composition as claimed in any one of claims 1 to 3 in the preparation of an anti-itch product; the product comprises medicine, skin care product or cosmetic.
9. The use according to claim 8, wherein the itch is itch caused by dermatitis, burns, eczema, urticaria, xeroderma, superficial fungal infections, or psoriasis.
10. The use of claim 8, wherein said itch is itch caused by diabetes, cholestasis, chronic kidney disease, tumors, or AIDS.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210248498.8A CN114539092B (en) | 2022-03-14 | 2022-03-14 | Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210248498.8A CN114539092B (en) | 2022-03-14 | 2022-03-14 | Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114539092A true CN114539092A (en) | 2022-05-27 |
| CN114539092B CN114539092B (en) | 2023-11-17 |
Family
ID=81663491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210248498.8A Active CN114539092B (en) | 2022-03-14 | 2022-03-14 | Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114539092B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070183996A1 (en) * | 2005-11-08 | 2007-08-09 | Sabrina Okombi | Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions |
| CN101401850A (en) * | 2008-11-11 | 2009-04-08 | 江西本草天工科技有限责任公司 | Piper hancei total alkaloid extract and uses thereof |
| KR101310980B1 (en) * | 2013-02-18 | 2013-09-25 | 주식회사 내추럴솔루션 | The cosmetics and functional food composition for improving anti-oxidant, anti-inflammatory and anti-wrinkling containing lycium chinense mill stem extracts |
| CN103508919A (en) * | 2012-06-25 | 2014-01-15 | 复旦大学 | Alkaloid compound and use of the same in preparation of anti-complement drugs |
| CN107805257A (en) * | 2017-09-12 | 2018-03-16 | 烟台大学 | A kind of capsule of weeping forsythia alkaloid extract and its preparation method and application |
| US20200289458A1 (en) * | 2017-09-22 | 2020-09-17 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
| CN115417788A (en) * | 2022-08-31 | 2022-12-02 | 中国人民解放军空军军医大学 | Anti-inflammatory compound and preparation method and application thereof |
-
2022
- 2022-03-14 CN CN202210248498.8A patent/CN114539092B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070183996A1 (en) * | 2005-11-08 | 2007-08-09 | Sabrina Okombi | Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions |
| CN101401850A (en) * | 2008-11-11 | 2009-04-08 | 江西本草天工科技有限责任公司 | Piper hancei total alkaloid extract and uses thereof |
| CN103508919A (en) * | 2012-06-25 | 2014-01-15 | 复旦大学 | Alkaloid compound and use of the same in preparation of anti-complement drugs |
| KR101310980B1 (en) * | 2013-02-18 | 2013-09-25 | 주식회사 내추럴솔루션 | The cosmetics and functional food composition for improving anti-oxidant, anti-inflammatory and anti-wrinkling containing lycium chinense mill stem extracts |
| CN107805257A (en) * | 2017-09-12 | 2018-03-16 | 烟台大学 | A kind of capsule of weeping forsythia alkaloid extract and its preparation method and application |
| US20200289458A1 (en) * | 2017-09-22 | 2020-09-17 | Inmed Pharmaceuticals Inc. | Topical formulations of cannabinoids and use thereof in the treatment of pain |
| CN115417788A (en) * | 2022-08-31 | 2022-12-02 | 中国人民解放军空军军医大学 | Anti-inflammatory compound and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| CHOI, E. J等: "Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4+ cells", 《JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY》, vol. 34, no. 01, pages 613 - 619 * |
| JINGXIAN ZHANG等: "Characterization and profiling of phenolic amides from Cortex Lycii by ultra-high performance liquid chromatography coupled with LTQ-Orbitrap mass spectrometry", 《ANALYTICAL AND BIOANALYTICAL CHEMISTRY》, vol. 407, pages 581 - 595, XP035431022, DOI: 10.1007/s00216-014-8296-4 * |
| PEDERSEN, HANS A等: "Cinnamoylphenethylamine 1H-NMR chemical shifts: a concise reference for ubiquitous compounds", 《NATURAL PRODUCT COMMUNICATIONS》, vol. 05, no. 08, pages 1259 - 1262 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114539092B (en) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2878305A1 (en) | Pharmaceutical composition for preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredientcomposition pharmaceutique pour la prévention ou le traitement de maladies médiées par stat-3, contenant un extrait ou une fraction de salvia plebeia r. br. en tant que principe actif | |
| EP3527206A2 (en) | Composition for preventing or treating hepatitis containing monoacetyl diacylglycerol compound | |
| JP7060500B2 (en) | A method for producing a pharmaceutical composition, a method for producing a quasi-drug composition, a method for producing a feed composition, and a method for producing a drinking water additive. | |
| CN104379155A (en) | Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| WO2017111069A1 (en) | Antipruritic | |
| CA2434574A1 (en) | An antiallergic agent | |
| KR101510936B1 (en) | Composition comprising extract of Martensia bibarii for prevention and treatment of autoimmune disease or inflammatory disease | |
| JPWO2007138961A1 (en) | Macrophage migration inhibitory factor inhibitor | |
| CN114539092B (en) | Oat bran phenolic amide alkaloid, preparation method thereof and application thereof in preparation of antipruritic products | |
| ES2941463T3 (en) | Compositions for the treatment of atopic dermatitis | |
| JP5923375B2 (en) | CGRP response promoter | |
| JP2007031302A (en) | Adiponectin production accelerator and metabolic syndrome preventive | |
| JP4325908B2 (en) | Lipolysis accelerator, skin external preparation and food and drink using the same | |
| JP2021169465A (en) | Composition for preventing or treating psoriasis containing monoacetyl diacylglycerol compound | |
| KR102119795B1 (en) | Anti-inflammatory Composition Comprising Broccoli Extract | |
| KR101708761B1 (en) | Composition for preventing or treating atopic dermatitis comprising purine derivative or its salt | |
| KR101069179B1 (en) | Composition for Treating Atopic Dermatitis Comprising Hirsutenone as an Active Ingredient | |
| TWI600429B (en) | Uses of ergosterol | |
| WO2013085346A1 (en) | Novel phytosphingosine derivatives, and composition comprising same for preventing and treating inflammatory skin diseases, autoimmune diseases, and hyperkeratosis diseases | |
| WO2024221689A1 (en) | Use of jak-hadc dual-target inhibitor and drug for treating inflammatory skin diseases | |
| CN114099493B (en) | Active compound for inhibiting insulin resistance and application thereof | |
| JP7396585B2 (en) | Composition for suppressing TSLP gene expression, suppressing IL-33 gene expression, or promoting filaggrin production | |
| EP2617707B1 (en) | Novel compound accelerating secretion of human-derived anti-microbial peptide, method for preparing same, and composition having same as active ingredient | |
| KR20170092490A (en) | Pharmaceutical composition for prevention or treatment of immune diseases comprising 4-hydroxy-2,3-dimethyl-2-nonen-4-olide | |
| KR20180111280A (en) | Composition for preventing and treating inflammatory bowel disease comprising sagassum serratifolium extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |